Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MIRA with free AI briefings, catalyst countdowns, and dilution alerts.

MIRA · MIRA PHARMACEUTICALS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.1M Cash on Hand
20.2mo Cash Runway
Follow MIRA by email Get an email when MIRA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MIRA, unsubscribe in one click. Privacy

📣 What MIRA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ketamir-2 Healthy Adult Participants Phase 1 · NCT07791303 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MIRA holds $8.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.2M/quarter from operations, an estimated runway of 20.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 58 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MIRA files for a raise →

👥 Who Owns MIRA

Insiders 18.6% Institutions (24 holders) 5.9% Public and other holders 75.5%
HolderTypeShares% of sharesAs of
Erez Aminov
Chief Executive Officer, Director · +7.53M options
Insider 3,592,666 8.55% 2025-12-31
MIRA PHARMACEUTICALS, INC.
10% owner
Insider 3,521,127 8.38% 2025-09-29
Brian Patrick McNulty
10% owner
Insider 670,000 1.59% 2024-08-28
Denil Nanji Shekhat
Director · +166,666 options
Insider 22,378 0.05% 2025-10-01

Share count 42,022,087 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MIRA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MIRA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.